SIRT1 and cancer: Alpha-cyano-4-hydroxycinnamate, a lactate transporter inhibitor, may also promote SIRT1 overexpression and decreased N-cadherin expression of cancer cells, leading to reduced tumor cell migration and reduced cancer cell aggressiveness in RCC [26].